|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| PharmaVitae: Company Comparator Tool |
|
|
|
|
€ 36 480,00 |
Editeur
: |
Datamonitor |
Langue
: |
Anglais |
Date de publication : |
Février 2008 |
Taille du document : |
1 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
The UK piling Market
40 pages | Mai 2002 |
This report will enable you to:Analyse the size of the UK market for piling between 1997 and 2006Quantify the size of the UK market for piling, 1997-2006, by technique: - bored - driven - embedded |
365,00 €
|
| |
| |
OTC Cough and Cold Remedies in Germany
15 pages | Juillet 2002 |
The German market for OTC cough and cold remedies reached a value of Euro 972 million (US$ 918 million) in 2001, up 0.4% on the previous year.
During the review period, the market grew by 9.4%, an |
198,00 €
|
| |
| |
The Cardiovascular Outlook 1998-2010
186 pages | Août 1999 |
In 1998, the global cardiovascular market expanded by 7.2%, growing in value from $60bn in 1997 to almost $65bn in 1998.
Market expansion is being driven by expanding prevalent populations in t |
795,00 €
|
| |
| |
The Japanese Pharmaceutical Market Outlook 2001
142 pages | Août 2001 |
Although Japan is the second largest pharmaceutical market in the world, it has traditionally been a relative 'no-go' area for pre-eminent Western drug companies.
Now, however, extensive cultur |
1 200,00 €
|
| |
| |
Healthcare In Northern Ireland
52 pages | Mai 2000 |
The Northern Ireland Presentation Includes:- The Structure Of The Health Service In Northern Ireland- Total Expenditure On Health & Personal Social Services- Number Of Inpatient Beds, BY Area- Occ |
327,00 €
|
| |
| |
Patient Power Outlook 2001
152 pages | Juillet 2001 |
The increase in patient power witnessed over the last decade has been driven by developments in healthcare systems, patient advocacy activity, the increasing influence of the media in healthcare issue |
955,00 €
|
| |
| |
Healthcare In Scotland
52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E |
327,00 €
|
| |
| |
The Diagnostics Outlook to 2005
130 pages | Février 1999 |
Diagnostic market : The current in vitro diagnostic (IVD) market is discussed, identifying how the market can be segmented according to country, end user, clinical speciality and disease area.
795,00 €
|
|
| |
| |
European Pharmaceutical Industry
35 pages | Juillet 2002 |
The Pharmaceutical industry remains one of Europe’s best performing sectors (employment, R&D and trade surplus).
The world pharmaceutical market was worth an estimated € 392,640 million (at ex-fact |
600,00 €
|
| |
| |
Patient Power in the Pharmaceutical Industry: The shift towards more informed, more powerful consumers of drugs
119 pages | Juin 1999 |
The dramatic rise in patient power in recent years presents a new and challenging opportunity to pharmaceutical companies, healthcare providers and governments alike.
A great need exists for ph |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| PharmaVitae: Company Comparator Tool |
|
|
Introduction
The Comparator Tool builds from the PharmaVitae profiles of the 50 leading pharma companies. Updated monthly, the tool allows you to compare the 50 players by current and forecast sales to 2012.
Scope
Highlights
Reasons to Purchase
Compare players by US or global forecast therapy area sales and portfolio breakdown measures to identify winners and losers over the next seven yearsDrill down to the individual drug forecast level for each company, identifying the key drivers behind forecast performance over the next seven yearsAccess over 150,000 continuously tracked data points analyzing current and future trends in the pharmaceutical and biotech arenas
|
|
ABOUT DATAMONITOR 2
OVERVIEW 4
This product contains forecasts for the leading 50 pharma companies-the PharmaVitae universe-across the seven major markets from 2007 to 2012. It has been designed for delivery as an Excel Interactive Model, please download the Interactive Model to your desktop and open in Excel (as opposed to opening directly in Explorer). For more detail about the Comparator Tool, please see the accompanying PowerPoint slide pack. 4
Please select the Interactive Model option from the download menu at the right-hand side of the page to access the model, ensuring you download the model to your desktop then open in Excel. 4
In the event of technical difficulties, please also ensure that your version of Excel contains the latest service pack update from Microsoft: http://office.microsoft.com/downloads/default.aspx 4
In the event of further technical issues, please contact PharmaVitae@datamonitor.com for assistance 4
Introduction 4
The Comparator Tool builds from the PharmaVitae profiles of the 50 leading pharma companies. Updated monthly, the tool allows you to compare the 50 players by current and forecast sales. 4
Key reasons to read this report 4
Forecasting methodology 5
The forecasting model 5
Company-reported & analyst consensus data 6
|
|
|
PPLSEN
|
|
|
|
|
